AnchorWatch Trust Company has started offering qualified custody services for Bitcoin under its Nevada trust charter, targeting institutions and high-net-worth individuals. The company charges a fixed-dollar fee based on vault size, with a maximum monthly fee capped at $10,000, providing clients with predictable custody costs. Optional insurance is also available. This new service adds a Nevada-chartered custody option for fiduciaries, public companies, trusts, and wealthy clients seeking secure Bitcoin custody.
AnchorWatch's new Bitcoin custody service is context for cryptocurrency market data. For readers following crypto, here is Pluang's market snapshot as of Oct 20, 2026 03:42 WIB: 46 of 50 major cryptocurrencies rose. Litecoin (LTC) is at Rp1.074.528 with a 5.12% gain and 73% sell order activity. The Graph (GRT) rose 4.93% to Rp428, with 84% sell orders. Bitcoin Cash (BCH) gained 4.79% to Rp4.980.361, with 53% buy orders and a typical hold time of 69 days.
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
On October 19, 2026, several stocks saw significant declines. Iambic Therapeutics dropped 31.4% but stayed just above its IPO price of $16 after raising $150 million. TCGX Acquisition fell 18.5% following its announcement of a merger with TriGemX Bio...
